Is there a human homologue to the murine proteolysis-inducing factor?

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 4984-4992

  Wieland, Barbara M ^a   Stewart, Grant D ^b   Skipworth, Richard J E ^b   Sangster, Kathryn ^b   Fearon, Kenneth C H ^b   Ross, James A ^b   Reiman, Tony J ^a   Easaw, Jay ^a   Mourtzakis, Marina ^a   Kumar, Vishesh ^a   Pak, Brian J ^c   Calder, Kathryn ^a   Filippatos, Gerasimos ^d   Kremastinos, Dimitris T ^d   Palcic, Monica ^a   Baracos, Vickie E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c CIPHERGEN BIOSYSTEMS INC   (United States)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PROTEOLYSIS INDUCING FACTOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PROTEOGLYCAN; PROTEOLYSIS INDUCING PEPTIDE; PROTEOLYSIS-INDUCING PEPTIDE;

ANTIBODY AFFINITY; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENE EXPRESSION; GLYCOSYLATION; HEART FAILURE; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TWO DIMENSIONAL ELECTROPHORESIS; ANIMAL; CHEMISTRY; CONGESTIVE HEART FAILURE; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE; NEOPLASM; TUMOR CELL LINE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE, TUMOR; GLYCOSYLATION; HEART FAILURE, CONGESTIVE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; WEIGHT LOSS;

EID: 34548855367     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0946     Document Type: Article

References (37)

1. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997;76:1035-40.
2. Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998;78:850-6.
3. Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 1999;59:5507-13.
4. Wyke SM, Tisdale MJ. NF-κB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 2005;92:711-21.
5. Todorov PT, Deacon M, Tisdale MJ. Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997;272:12279-88.
6. Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997;76:606-13.
7. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
8. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001;84:1599-601.
9. Williams ML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J, Wainer IW. The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest 2004;22:866-70.
10. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressinga novel cancer cachectic factor. Br J Surg 2000;87:53-8.
11. Jatoi A, Foster N, Wieland B, et al. The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Dis Esophagus 2006;19:241-7.
12. Deans DA, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KC, Ross JA. Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastrooesophageal malignancy. Br J Cancer 2006;94:731-6.
13. Cunningham TJ, Hodge L, Speicher D, et al. Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin. J Neurosci 1998;18:7047-60.
14. Cunningham TJ, Jing H, Akerblom I, Morgan R, Fisher TS, Neveu M. Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol 2002;177:32-9.
15. Hipfel R, Schittek B, Bodingbauer Y, Garbe C. Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. Br J Cancer 2000;82:1149-57.
16. Schittek B, Hipfel R, Sauer B, et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2001;2:1133-7.
17. Monitto CL, Dong SM, Jen J, Sidransky D. Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res 2004;10:5862-9.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
19. Lafitte D, Dussol B, Andersen S, et al. Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples. Clin Biochem 2002;35:581-9.
20. Choudhary G, Chakel J, Hancock W, Torres-Duarte A, McMahon G, Wainer I. Investigation of the potential of capillary electrophoresis with off-line matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for clinical analysis: examination of a glycoprotein factor associated with cancer cachexia. Anal Chem1999;71:855-9.
21. Dai Y, Whittal RM, Li L. Two-layer sample preparation: a method for MALDI-MS analysis of complex peptide and protein mixtures. Anal Chem 1999;71:1087-91.
22. Cadieux PA, Beiko DT, Watterson JD, et al. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal 2004;18:170-5.
23. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998;85:115-22.
24. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004;97:2333-8.
25. Wang Z, Corey E, Hass GM, et al. Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer 2003;105:123-9.
26. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-7.
27. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-8.
28. Palomares MR, Sayre JW, Shekar KC, Lillington LM, Chlebowski RT. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996;78:2119-26.
29. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
30. Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M, Tisdale MJ. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996;56:1256-61.
31. Teich N, Kleeff J, Lochs H, et al. The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterol 2005;5:20.
32. Sato C, Kim JH, Abe Y, Saito K, Yokoyama S, Kohda D. Characterization of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence of recombinant human epidermal growth factor receptor. J Biochem (Tokyo) 2000;127:65-72.
33. Lowrie AG, Wigmore SJ, Wright DJ, Waddell ID, Ross JA. Dermcidin expression in hepatic cells improves survival without N-glycosylation, but requires asparagine residues. Br J Cancer 2006;94:1663-71.
34. Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer 1999;80:1734-7.
35. Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST. Different techniques for urinary protein analysis of normal and lungcan cer patients. Proteomics 2005;5:1140-9.
36. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83.
37. Luo Y, Zhang LL, Ning L, He DL, Fan JH, Hou HL. [Establishment of bone metastasis model of prostate cancer in nude mice by intratibia injection of human prostate cancer cell line Du145]. Zhonghua Nan Ke Xue 2006;12:133-6.